With the support of Dr. Thilo Pfletschinger from 3DSE, we developed the company strategy for Staburo for the next five years. Before the workshop, all employees gave input to possible goals and the prospects of Staburo. The final strategy includes all our common goals and gives guidance, how to achieve them. Our clients profit from our support in biostatistics and statistical programming – now and in the future!

We are very happy to welcome Laura Schlieker in our team. Laura will support our clients with her experience in biostatistics, especially within the area of Translational Medicine & Biomarkers. We are looking forward to a great cooperation!

The presentation was about the current guideline for sample size calculations that is in place at Staburo. This guideline has been presented to the whole team and is intended to help everybody, when performing such calculations in his/her projects.

The first version of this guideline has been finalised and contains already some settings (such as evaluations with binary or time-to-event endpoints). However, the objective is that all colleagues get involved and share their experience (different types of trial settings/designs, of endpoints). Indeed, each project has its own specifics, each colleague has his/her own expertise areas and is therefore able to contribute to improve the guideline. On the other side, this guideline will help in new projects with similar questions as previous ones, since it gathers earlier experience.

Ideally, each setting contains the following parts: assumptions and methodology used with corresponding references, example of program doing the calculation (using SAS or other adapted), and template text for protocol.

As a conclusion, this guideline will bring benefit to new projects and further improve the quality of our handling of customers‘ requests!

Another publication with Staburo biostatistics support, this time in diabetes type 2.

Background: Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients with T2D who represented a primary cardiovascular disease prevention population.

The full publication can be found here: https://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0493-3

Enjoy reading!

Feel free to reach out to us if you need support in your study!

Staburo delivered biostatistics services in this bioavailability study.

The development of several disorders, such as cardiovascular diseases, diabetes and osteoporosis, has been linked to suboptimal dietary magnesium (Mg) intake. In this context, a number of studies have tried to investigate which Mg compounds are best suited for Mg supplementation. Results suggest that organic Mg compounds are superior to the inorganic Mg oxide in terms of bioavailability, but a reliable statement cannot yet be made due to systematic differences in the applied study designs.

The full publication can be read here: https://bmcnutr.biomedcentral.com/articles/10.1186/s40795-016-0121-3

Feel free to reach out to us if you need support in your study!

The Staburo SAS programming environment facilitates the creation of meaningful outputs, such as tables, listings and figures (TLFs), from client supplied data.

This process consists of two key steps:

From raw data to intermediate derived data:
Data supplied by the client is not easily turned directly into desired outputs. The first step groups and formats raw input and also calculates new needed data elements. Data and programs are examined for issues and errors.

From intermediate derived data files to TLF outputs:

During this step, statistical analyses are performed and TLF outputs produced.

Finally, all programs are scanned for error and warning messages and programs involved in the process are validated by a second programmer.